Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | What is in the future for T-cell lymphoma?

Owen O'Connor • 9 Jun 2016
EHA 2016
Non-Hodgkin Lymphoma T-Cell Lymphoma Chidamide Pralatrexate Romidepsin Vorinostat

Owen O’Connor, MD, PhD from Columbia University Medical Center, New York, NY discusses the positive trend in the research for treating T-cell lymphoma. The last 5 years have been extraordinary with the development of HDAC inhibitors, with three approved world wide – vorinostat and romidepsin in the US and chidamide in China. Dr O’Connor mentions how he was sceptical about adding these new drugs to CHOP backbones. He also discusses the presentation at ASH which outlined studies investigating combinations of pralatrexate and romidepsin, and combinations of hypomethylating agents and HDAC inhibitors. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

More from Owen O'Connor

6:47
Immunoepigenetic platforms for PTCL treatment
Owen O'Connor • 2 Jul 2019
4:42
PTCL arising as a PTLD: the efficacy of pralatrexate
Owen O'Connor • 19 Jun 2019
9:20
The role of epigenetic modulators in the pathogenesis of lymphomas
Anas Younes et al. • 18 Sep 2017
iwNHL 2017: The future of lymphoma research and treatment
Catherine Bollard et al. • 8 Sep 2017

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals